Shelton Capital Management Nektar Therapeutics Transaction History

Shelton Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	BUY	$4.16 - $13.72 $6,714 - $22,144	1,614 Added 15.75%	11,864 $64,000
Q2 2020 Aug 12, 2020	SELL	$16.86 - $23.44 $8,092 - $11,251	-480 Reduced 4.47%	10,250 $237,000
Q1 2020 May 13, 2020	SELL	$14.47 - $27.96 $12,400 - $23,961	-857 Reduced 7.4%	10,730 $192,000
Q4 2019 Feb 11, 2020	BUY	$15.87 - $23.12 $183,885 - $267,891	11,587 New	11,587 $250,000
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $800,844 - $1.51 Million	-13,952 Closed	0 $0

Q3 2017 Nov 14, 2017	SELL	$17.79 - $24.0 $23,678 - $31,944	-1,331 Reduced 8.71%	13,952 $335,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,696 Added 12.48%	15,283 $299,000
Q1 2017 Nov 28, 2017	BUY	N/A	2,392 Added 21.37%	13,587 $319,000
Q3 2016 Dec 04, 2017	BUY	N/A	11,195	11,195 $137,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

Stay updated on Shelton Capital Management with notifications on news.